A report from the European Commission highlights how the enforcement of pharmaceutical antitrust rules between 2018 and 2022 increased the availability of fairly priced innovative medicines in the bloc.
The European Commission and national competition authorities imposed fines exceeding €780m ($846m) in relation to 26 cases of pharmaceutical product anti-competitive practices between 2018 and 2022, a new report from the commission has revealed.
These sanctions were made for a variety of reasons, including the misuse of the EU drug patent system to prolong market exclusivity, disparagement of a competitor's products to protect the...
The European Medicines Agency’s chief medical officer Steffen Thistrup argued that patients are able to understand the “complex regulatory and scientific issues” that the EMA committees discuss when they assess drugs.
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
EU marketing applications for drugs aimed at slowing myopia progression in children and for treating cutaneous T-cell lymphoma have been turned down by the European Medicines Agency.
